4,5-dihydro-4,4-dialkyl-6-(substituted)phenyl-3(2H)-pyridazinones useful as cardiotonic agents

Abstract

Novel 4,5-dihydro-4,4-dialkyl-6-(substituted)phenyl-3(2H)-pyridazinones having unexpected activity for use as cardiotonic and antihypertensive agents.

Description

This is a continuation of U.S. application Ser. No. 685,640 filed Dec. 24, 1984, now abandoned.

BACKGROUND OF THE INVENTION

Substituted 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones and 6-(substituted)phenyl-3(2H)-pyridazinones useful as cardiotonic agents are the subject of U.S. Pat. No. 4,353,905 and U.S. application Ser. No. 477,695 filed Mar. 22, 1983 now 4,734,415. Additional references are cited therein to other known compounds.

SUMMARY OF THE INVENTION

The present invention relates to novel 4,5-dihydro-4,4-dialkyl-6-(substituted)phenyl-3(2H)-pyridazinone compounds having unexpectedly superior activity as cardiotonic agents of the formula ##STR1## wherein Q is oxygen or sulfur; R₂ and R₃ are independently hydrogen or lower alkyl; R₄ and R₅ are independently lower alkyl; Y is H, halogen, lower alkyl, lower alkoxy, or a group such as ##STR2## where R_d and R_e are independently H, lower alkyl, (CH₂)_n R_f where R_f is a benzene ring optionally substituted by halogen, hydroxy, lower alkyl, lower alkoxy, and CF₃, and n is zero to three, and A is any of the groups from a-e, and is attached to the 3- or 4-position of the phenyl ring: ##STR3## wherein R₁, R', and R are independently hydrogen or lower alkyl, CH₂ OH, SCH₃, SOCH₃, SO₂ CH₃, hydroxyalkyl, halogen, (CH₂)_k NR" R"', wherein k is zero to two and R" and R"' are independently hydrogen or lower alkyl, wherein lower alkyl contains one to six carbon atoms; or, when attached to the 4- and 5-positions of the imidazole ring, may be taken together to form a (i) 5-, 6-, or 7-membered ring which may also contain a nitrogen atom, (ii) benzene ring which is optionally substituted by halogen, hydroxy, lower alkyl, and lower alkyloxy, and (iii) pyridine ring; X is a bond, (CH₂)_n or O(CH₂)_n wherein n is one to four; ##STR4## wherein

(i) W=L=Z=CH

(ii) W=Z=N and L=CH or

(iii) L=Z=N and W=CH; and X is a bond, (CH₂)_n or O(CH₂)_n+1 wherein n is 1 to 4; ##STR5## wherein R₆ is hydrogen, alkyl, COR₇ where R₇ is a benzene ring optionally substituted by halogen, lower alkyl, hydroxy, lower alkoxy, and CF₃ or (CH₂)_n R₇ where n is zero to four and R₇ is the same as defined above; or ##STR6## wherein R₈ and R₉ are independently hydrogen, lower alkyl, aryl, hydroxy, lower alkoxy, NHR₁7 where R₁7 is hydrogen, lower alkyl or lower alkanoyl, CO₂ R₁8 where R₁8 is hydrogen or lower alkyl, OCOBR₁0 where R₁0 is alkyl, aryl or heteroaryl and B is a direct bond or NH, or R₈ and R₉ taken together, are carbonyl or ethylenedioxy; ##STR7## wherein represents a double or single bond between two carbon atoms; R₁1 is hydrogen or lower alkyl; M is NH, O, or S, and X is either a direct bond or NH; or ##STR8## where X, M, and R₁1 are the same as defined above; or

e. A=NHPR₁2 R₁3 wherein P is a bond or carbonyl; R₁2 is lower alkyl, straight or branched; R₁3 is H, NR₁4 R₁5 wherein R₁4 and R₁5 are individually hydrogen, lower alkyl straight or branched or taken together to form a 5-, or 6-, or 7-membered ring or a group as defined as 1a-1c: or S(O)_n R₁6 where n is zero to two and R₁6 is lower alkyl straight or branched, phenyl;

and the pharmaceutically acceptable acid addition salts thereof.

Preferred compounds of formula I of the present invention are the compounds of formula I wherein Q is oxygen, Y is hydrogen, and A is ##STR9## wherein R, R₁, and R₂ are independently H or lower alkyl, R₁ and R₂ may be taken together to form a (i) five or six membered ring and (ii) benzene ring; or A is NHPR₁2 R₁3 wherein P is carbonyl, R₁2 is lower alkyl, and R₁3 is hydrogen and is attached to the four-position of the phenyl ring.

Most preferred compounds of the present invention are 4,5-dihydro-4,4-dimethyl-6-[4-(1H-imidazol-1-yl)phenyl]3(2H)pyridazinone and N-[4-(1,4,5,6-tetrahydro-5,5dimethyl-6-oxo-3-pyridazinyl)phenyl]-acetamide .

The present invention further relates to a cardiotonic composition for increasing cardiac contractility, said composition comprising an effective amount of a compound of formula I as defined above and a pharmaceutically acceptable carrier.

The present invention also relates to the method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or a liquid dosage form to such patient an effective amount of a compound of formula I as defined above.

The present invention relates to a pharmaceutical composition which also decreases blood pressure, said composition comprising an effective amount of a compound of formula I as defined above and a pharmaceutically acceptable carrier.

Finally, the present invention relates to the method of decreasing blood pressure in a patient requiring such treatment which comprises administering to such patient an effective amount of a compound of formula I as defined above.

DETAILED DESCRIPTION OF THE INVENTION

The detailed description of a cardiotonic composition and the pharmaceutical composition, which may be used for the compound of formula I above in combination with a pharmaceutically acceptable carrier, but not considering the unexpected activity of the present invention may be found in the above noted U.S. Pat. No. 4,353,905 and U.S. application Ser. No. 477,695 filed Mar. 22, 1983, which therefore, are hereby incorporated by reference. In the same manner the method of using the present compounds of formula I for increasing cardiac contractility and decreasing blood pressure can be ascertained from U.S. application Ser. No. 477,695 filed Mar. 22, 1983, when appropriately noting the unexpectedly relative activity of the present formula I compounds. The relative activity is as set out hereinafter.

The compounds of the present formula I are also useful in both the free base form and in the form of acid addition salts as described in U.S. application Ser. No. 477,695.

The terms "lower" in reference to alkyl and alkoxy, as well as "halogen" are as defined in U.S. application Ser. No. 477,695.

The relative activity showing unexpectedly superiority for the compounds of the present invention compared to those of the closest compounds of U.S. application Ser. No. 477,695 is shown in the following table.

TABLE
__________________________________________________________________________
##STR10##
% Change
Compound       Dose  Myocardial
Heart Blood
Ex. R3
R4
R5
(mg/kg)
Contractility
Rate  Pressure
__________________________________________________________________________
H    H  H  0.01  9       -4.0  -2.0
0.03  32      -4.0  -6.0
0.10  57      -1.0  -10.5
0.31  87      2.0   -21.5
n = 1
H    CH3
H  0.01  0.5     -1.0  0
0.03  -2.0    -4.5  -1/-1
0.10  8.0     -4.5   0/-1
0.31  26.5    -1.5    -5/-9.5
1.0   61.0    3.0     -7/-14.5
1*  H    CH3
CH3
0.01  15.0    1.5     -1/-1.5
n = 1          0.03  34.0    4.0    -6/-10
0.10  70.0    17.0    -11/-16.5
0.31  101.5   21.5  -22/-34
1.0   99.0    30.5   -21.5/-31.5
n = 5
CH3
H  H  0.01   50.6 ± 11.2
6.0 ± 5.3
-1.7 ± 1.1
n = 5          0.03  124.0 ± 29.4
25.2 ± 8.2
-7.4 ± 1.3
n = 6          0.10  148.5 ± 22.5
43.8 ± 12.0
-19.0 ± 1.3
n = 4          0.31  118.5 ± 31.7
47.5 ± 15.5
-35.2 ± 1.3
n = 3          1.0    58.6 ± 12.9
33.3 ± 13.3
-45.0 ± 4.9
n = 1
CH3 CH3
H  H  0.01  1       0     1/0
0.03  5       0     -1/-2
0.1   20      1     -1/- 2
0.31  73      5     -8/-9
1.0   98      15    -15/-17
__________________________________________________________________________
n = number of tests
*Compound of the present invention

The test procedure for methods of use of the present invention, are as described in U.S. application Ser. No. 477,695.

The following Example further illustrates the present invention without, however, limiting thereto.

EXAMPLE 1

PAC 4,5-Dihydro-4,4-dimethyl-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone

Imidazole (0.70 g, 0.013 mol) and methyl α,α-dimethyl-4-fluoro-γ-oxobenzene butanoate (2.85 g, 0.012 mol) are dissolved in dimethyl sulfoxide (12.0 ml) in which freshly pulverized potassium carbonate (5.80 g, 0.042 mol) is suspended. The resulting mixture is stirred and heated at 100°-110° for 12 hours. The mixture is then cooled to room temperature and poured into 100 ml of ice water and stirred for ten minutes. The solid is filtered to give 2.14 g of methyl α,α-dimethyl-4-(1H-imidazol-1-yl)-γ-oxobenzene butanoate, mp 89°-93°C

Methyl-α,α-dimethyl-4-(1H-imidazol-1-yl)γ-oxobenzene butanoate (1.8 g, 0.0066 mol) is dissolved in ethanol (25 ml) and 1.0 ml of 54% aqueous hydrazine is added. The resulting mixture is refluxed for ten hours, then another 0.5 ml aqueous hydrazine is added and the mixture is refluxed for an additional four hours.

The solution is evaporated to dryness and the residue is triturated with a small volume of ice-cold ethanol and collected on a suction funnel to give 1.2 g of the title compound, mp 199°-200°C

Calcd. for C₁5 H₁6 N₄ O; C, 67.14; H, 6.01; N, 20.89. C, 66.91; H, 5.88; N, 20.74.

Claims

1. A compound of the formula: ##STR11## wherein Q is oxygen or sulfur; R₂ and R₃ are independently hydrogen or lower alkyl; R₄ and R₅ are independently lower alkyl.

2. A compound of claim 1 wherein Q is oxygen; Y is hydrogen, and A is ##STR12## and is attached to four-position of the phenyl ring; wherein R, R₁, and R₂ are H or lower alkyl; R₁ and R₂ may be taken together to form a (i) five or six membered ring and (ii) benzene ring.

3. A compound of claim 1 wherein Q is oxygen, Y is hydrogen, and A is NHPR₁2 R₁3 wherein P is carbonyl, R₁2 is lower alkyl, and R₁3 is hydrogen and is attached to the four-position of the phenyl ring.

4. A compound of claim 3 wherein the compound is N-[4-(1,4,5,6-tetrahydro-5,5-dimethyl-6-oxo-3-pyridazinyl)phenyl]-acetamid e.

5. A compound of claim 2 wherein the specific embodiment is 4,5-dihydro-4,5-dimethyl-6-[4-1H-imidazol-1-yl)phenyl-3(2H)-pyridazinone.

6. A pharmaceutical composition for increasing cardiac contractility comprising an amount effective for increasing cardiac contractility or a compound as claimed in claim 1 with a pharmaceutically acceptable carrier.

7. The method for increasing cardiac contractility in a patient requiring such treatment comprising administering to such patients an effective amount of the composition of claim 6.

8. The method for lowering blood pressure in a patient suffering from hypertension comprising administering to such patients an effective amount of a composition of claim 6.